Swissmedic has issued an urgent announcement concerning the recall of a specific batch of the veterinary medicine Revozyn RTU 400 mg/ml injection suspension for cattle. If you work in veterinary clinics or regulatory roles within the livestock industry, this update is critical.
The affected batch (25B023) is being recalled down to the level of veterinarians in retail settings. This decision underscores the need for vigilance and swift action to ensure compliance and safety standards. The recall applies within Switzerland and is effective immediately.
What changed in the recall?
Swissmedic announced the immediate recall of batch 25B023 of Revozyn RTU 400 mg/ml injections. The product’s suspension is primarily used for cattle and intended to treat serious infections. The recall stems from concerns related to safety or compliance issues, although specific causes were not listed in the notice.
Per Swiss regulations, veterinary product recalls are conducted to rapidly mitigate risks, including potential harm to animal health or violations of manufacturing protocols. Affected products should be removed from circulation and returned according to the outlined process.
Who is affected?
This recall impacts veterinarians and clinics involved in prescribing and administering Revozyn RTU 400 mg/ml for cattle. Veterinary supply chains, retailers, and distributors holding stock of batch 25B023 must act immediately to align with Swissmedic’s directives.
Veterinary clinics should review inventory systems to identify any stock belonging to the recalled batch and cease further use or distribution. This action helps safeguard animal health and ensures compliance with regulatory expectations.
Why was this recall necessary?
Although Swissmedic has not publicly detailed the reasoning for the recall, such actions are typically driven by identified safety risks, product quality issues, or manufacturing discrepancies. Veterinary medicines are held to stringent standards under Swiss medical device regulations to ensure efficacy and safety.
Swissmedic continually monitors veterinary medicines authorized within Switzerland. A recall decision acts as a precautionary measure and emphasizes the commitment to public health and regulatory scrutiny. Stakeholders should follow Swissmedic protocols to properly discard and replace affected batches.
FAQ
Q1: What should veterinarians do with the recalled batch?
A1: Veterinary clinics and retailers should immediately halt use of batch 25B023 and contact the relevant Swissmedic channels for instructions on the return process. Discard or refund requests may apply depending on inventory conditions.
Q2: Will there be replacement stock available?
A2: Swissmedic has not issued guidance on replacement stock. Veterinarians should consult suppliers or manufacturers directly for updates and alternative medicines.
Q3: Is only Switzerland impacted?
A3: This recall is specific to Switzerland. If you operate internationally, contact respective authorities to determine regional product safety alerts.
Conclusion
Veterinary and clinical teams should act promptly by removing batch 25B023 of Revozyn RTU 400 mg/ml from inventory. Such recalls emphasize strict adherence to safety protocols and commitment to animal health. Ensure proper compliance with this regulatory action and consult Swissmedic for further guidance.
Disclaimer
This article is for informational purposes and is not legal advice. Refer directly to Swissmedic notices for official guidelines on veterinary recall procedures.
Source Information
For full information about the Swissmedic announcement, see the link below.